Details

Autor(en) / Beteiligte

• Wheatley, Adam K
• Juno, Jennifer A
• Wang, Jing J
• Selva, Kevin J
• Reynaldi, Arnold
• Tan, Hyon-Xhi
• Lee, Wen Shi
• Wragg, Kathleen M
• Kelly, Hannah G
• Esterbauer, Robyn
• Davis, Samantha K
• Kent, Helen E
• Mordant, Francesca L
• Schlub, Timothy E
• Gordon, David L
• Khoury, David S
• Subbarao, Kanta
• Cromer, Deborah
• Gordon, Tom P
• Chung, Amy W
• Davenport, Miles P
• Kent, Stephen J

Titel

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Ist Teil von

• Nature communications, 2021-02, Vol.12 (1), p.1162-1162, Article 1162

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B cell and T cell dynamics over time in a cohort of patients who have recovered from mild-moderate COVID-19. Binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection. A similar decline in Spike-specific CD4 and circulating T follicular helper frequencies occurs. By contrast, S-specific IgG memory B cells consistently accumulate over time, eventually comprising a substantial fraction of circulating the memory B cell pool. Modelling of the concomitant immune kinetics predicts maintenance of serological neutralising activity above a titre of 1:40 in 50% of convalescent participants to 74 days, although there is probably additive protection from B cell and T cell immunity. This study indicates that SARS-CoV-2 immunity after infection might be transiently protective at a population level. Therefore, SARS-CoV-2 vaccines might require greater immunogenicity and durability than natural infection to drive long-term protection.